Browsing: Pharma

Analysts at Guggenheim Securities predicted in a note to investors that established sales force and…

The FDA has issued two manufacturing-related Complete Response Letters (CRLs), putting the brakes on promising…

After a series of regulatory and clinical setbacks for Sanofi’s trebrutinib, the French drugmaker has…

Daiichi Sankyo has postponed the publication of its annual report by two weeks to allow…

Pfizer is teaming up with quarterback Fernando Mendoza to launch the next phase of its…

Pharmacologists, drug development executives, and regulatory professionals grapple with accelerating 2026 pharma trends amid tighter capital and shifting regulations. Discover AI integration, manufacturing reshoring, clinical pipelines, and FDA approvals.

Merck & Co. announces the long-awaited first publication of PD-1xVEGF bispecific data. China’s Zai Lab…

Edelman research shows that patients’ confidence in their ability to find answers to health questions…

Typically, at major pharmaceutical companies’ earnings conferences, executives talk enthusiastically about new products and tout…

And there was nothing. Regeneron’s announcement of a drug pricing agreement with the White House…